Tissue plasminogen activator (tPA) remains the only drug for recanalization in acute
ischemic stroke, and the dose is determined by the patient's body-weight. Properties of the …

Exposure to 2-MHz transcranial diagnostic ultrasound enhances the thrombolytic activity of
intravenously administered tissue plasminogen activator (IV-tPA) in acute ischemic stroke …

Thrombolytic therapy appears to be one of the most valuable treatments for acute ischemic
stroke. The major objective of thrombolysis in acute ischemic stroke is to recanalize …

In the pivotal clinical trials of intravenous tissue plasminogen activator (TPA) therapy for
ischemic stroke, a low rate of early arterial recanalization was suspected due to the small …

Combined ultrasound and tissue plasminogen activator (rt-PA) therapy, or ultrasound
enhanced thrombolysis (UET), has been shown to improve recanalization in patients with …

In the pivotal clinical trials of intravenous tissue plasminogen activator (TPA) therapy, a low
rate of early arterial recanalization was suspected because only a few stroke patients may …

Background. Tissue plasminogen activator (TPA) activity may be enhanced with ultrasound,
potentially 2 MHz transcranial Doppler (TCD). The authors present Phase I data of the …

Background and purpose: Treatment of acute ischemic stroke with intravenous recombinant
tissue plasminogen activator (rtPA) is relatively ineffective in patients with large vessel …

Background and Purpose—In thrombolytic therapy for acute ischemic stroke, it is essential to
obtain rapid thrombolysis before ischemic neuronal injury occurs. To develop a new …

Study Objectives: Stroke is a significant cause of mortality and morbidity in the US The
impact of this disease is expected to increase over time as the population ages …